Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02580058 · ClinicalTrials.gov registry record · Phase 3
A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)
A Phase 3 study of Ovarian Cancer, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 566
- Enrollment target
- 20
- Study locations
NCT02580058 is a Phase 3 study of Ovarian Cancer that has completed, run by Pfizer. The registered enrollment target is 566 participants, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (22% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT02580058, a Phase 3 study of Ovarian Cancer, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 566 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 3 global study comparing avelumab alone to avelumab plus PLD and to PLD alone to demonstrate that avelumab given alone or in combination with PLD is superior to PLD alone in prolonging Overall Survival in patients with platinum resistant/platinum refractory ovarian cancer.
Conditions Studied
Interventions
- DRUG PLD
- BIOLOGICAL avelumab
Study Locations (20)
Arizona
- Arizona Oncology Associates, PC - HAL - Chandler
- Arizona Oncology Associates, PC - HAL - Phoenix
- Arizona Oncology Associates, PC - HAL - Phoenix
- Arizona Oncology Associates, PC - HAL - Scottsdale
- Arizona Oncology Associates, PC-HAL - Tempe
- Arizona Oncology Associates, PC - HOPE - Tucson
- Arizona Oncology Associates, PC - HOPE - Tucson
California
- University of California, Irvine/UC Irvine Health - Orange
- Sansum Clinic - Santa Barbara
- Sansum Clinic - Solvang
Colorado
- Rocky Mountain Cancer Centers - Aurora
- Rocky Mountain Cancer Centers - Boulder
- Rocky Mountain Cancer Centers - Lakewood
Florida
- Florida Cancer Specialists - Daytona Beach
- Florida Cancer Specialists - Wellington
- Florida Cancer Specialists - West Palm Beach
Arkansas
- Highlands Oncology Group - Fayetteville
- Highlands Oncology Group - Rogers
Georgia
- Atlanta Gynecologic Oncology - Atlanta
- Northside Hospital - Pharmacy - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 566 participants |
| Start Date | 2015-12-21 |
| Est. Completion | 2022-07-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02580058
The ClinicalTrials.gov registry entry for NCT02580058 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 566 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (22% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which PLD is the first listed.
NCT02580058 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Arizona, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT02580058 about?
NCT02580058 is a clinical study titled "A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)". A Phase 3 global study comparing avelumab alone to avelumab plus PLD and to PLD alone to demonstrate that avelumab given alone or in combination with PLD is superior to PLD alone in prolonging Overall Survival in patients with platinum resistant/platinum refractory ovarian cancer.
What is the current status of trial NCT02580058?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 566 participants. The study started on 2015-12-21. Estimated completion is 2022-07-12.
What conditions does trial NCT02580058 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT02580058?
The interventions under investigation include: PLD (DRUG), avelumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02580058?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02580058 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
-
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RECRUITING · Phase 3
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RECRUITING · Phase 3
-
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.